Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-018-2604-x
Abstract: PurposeENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis.MethodsAttempting TFR required ≥ 3 years… read more here.
Keywords: phase; week; following frontline; treatment ... See more keywords